title: Administration of Lupinus albus gamma conglutin (Cγ) to n5 STZ rats augmented Ins-1 gene expression and pancreatic insulin content.
abstract: Several studies support the health-promoting benefits of lupins, particularly lupin proteins. It has been demonstrated that Lupinus albus gamma conglutin (Cγ) protein lowered blood glucose levels; thus, Cγ showed promise as a new anti-diabetic compound for type 2 diabetes (T2D) treatment. The aim of this study was to evaluate the effect of Cγ on Ins-1 gene expression and on pancreatic insulin content in streptozotocin-mediated diabetic rats. Cγ was isolated from Lupinus albus seeds. Its identification was confirmed with polyacrylamide gel electrophoresis under native and denaturing conditions. We used streptozotocin (STZ) to induce T2D on the 5th day of life of newborn male Wistar rats (n5-STZ). After 20 weeks post-induction, these animals (glycemia > 200 mg/dL) were randomly assigned to three groups that received the following one-week treatments: vehicle, 0.90% w/v NaCl (n5 STZ-Ctrl); glibenclamide, 10 mg/kg (n5 STZ-Glib); or Cγ, 120 mg/kg (n5 STZ-Cγ). Glucose and insulin levels were measured before and after treatment. Ins-1 gene expression was quantified using real time polymerase chain reaction and the pancreatic insulin content was evaluated with immunohistochemistry. Post-treatment, the n5 STZ-Cγ and n5 STZ-Glib groups showed reductions in glucose, increments in serum insulin, and increases in Ins-1 gene expression and beta cell insulin content compared to the n5 STZ-Ctrl group. The results showed that Cγ had beneficial effects on Ins-1 gene expression and pancreatic insulin content. These biological effects of Cγ strengthen its promising potential as a nutraceutical and/or new agent for controlling hyperglycemia.
authors.affiliation: Instituto de Enfermedades Crónico-Degenerativas, Departamento de Biología Molecular y Genómica, C.U.C.S., Universidad de Guadalajara, Guadalajara, Jalisco, México.
authors.forename: Belinda
authors.initials: B
authors.lastname: Vargas-Guerrero
authors.forename: Pedro M
authors.initials: PM
authors.lastname: García-López
authors.forename: Alma L
authors.initials: AL
authors.lastname: Martínez-Ayala
authors.forename: José A
authors.initials: JA
authors.lastname: Domínguez-Rosales
authors.forename: Carmen M
authors.initials: CM
authors.lastname: Gurrola-Díaz
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D015870:Gene Expression; D005905:Glyburide / Q000008:administration & dosage; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000235:genetics* / Q000378:metabolism; D050417:Insulin-Secreting Cells; D031297:Lupinus / Q000737:chemistry*; D008297:Male; D010179:Pancreas / Q000378:metabolism*; D010936:Plant Extracts / Q000008:administration & dosage; D010940:Plant Proteins / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010936:Plant Extracts; D010940:Plant Proteins; D013311:Streptozocin; D005905:Glyburide